trending Market Intelligence /marketintelligence/en/news-insights/trending/9PQGILbpqa1yJpMDwTBeOQ2 content esgSubNav
In This List

Bausch Health's Arazlo lotion for acne snags US FDA approval

Blog

Perspectivas América Latina 2023 Emerging Trends & Growth

Blog

Insight Weekly: SVB fallout limited; US rents up; renewable natural gas investments flow in

Blog

A Cloud Migration Plan for Corporations featuring Snowflake®

Blog

Investor Activism Campaigns Hit Record High in 2022


Bausch Health's Arazlo lotion for acne snags US FDA approval

Bausch Health Cos. Inc.'s Arazlo Lotion has been approved by the U.S. Food and Drug Administration to treat acne vulgaris in patients who are 9 and older.

Arazlo, also known as tazarotene 0.045%, was developed by Laval, Quebec-based Bausch's dermatology business Ortho Dermatologics Inc. and will launch in the first half of 2020 "to coincide with the start of acne season," Ortho Dermatologics President Bill Humphries said in a Dec. 19 press release.

During clinical trials, Arazlo improved the severity of noninflammatory and inflammatory lesions compared to a placebo drug, and also matched the efficacy and safety of a different acne treatment called Tazorac Cream 0.1%.

Acne, the most common skin condition in the U.S., affects about 50 million Americans. Acne stems from plugged hair follicles, leading to whiteheads, blackheads or pimples on the face, forehead, chest, upper back and shoulders.